(Q42506198)

English

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Serafin Morales

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Mafalda Oliveira

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Antonio Llombart-Cussac

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Laia Paré

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Patricia Galván

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Begoña Bermejo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Noelia Martínez

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Maria Vidal

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Sònia Pernas

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Rafael López

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Montserrat Muñoz

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Lorena de la Peña

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Alexandra Peláez

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Aleix Prat

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Paolo Nuciforo

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

24 February 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

545-554

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Deconstructing the molecular portraits of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of the intrinsic molecular subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant ovarian suppression in premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30021-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28238593%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42506198&oldid=1572687808"